ConferenceCancer Research · March 1, 2023
AbstractBackground During the COVID pandemic, we designed and implemented a program, called BQual-D, to maintain high quality care for patients with HR+, HER2 negative MBC who were taking oral anti-cancer th ...
Full textCite
ConferenceCancer Research · February 15, 2022
AbstractBackground: During the COVID pandemic, we designed and implemented a program, called BQual-D, to maintain high quality care for patients with HR+, HER2 negative MBC who were taking oral anti-cancer t ...
Full textCite
ConferenceCancer Research · February 15, 2020
AbstractBackground: Side effects of and adherence to aromatase inhibitors in women with ductal carcinoma in situ are not well described. Methods: Postmenopausal women in a prospective phase II study of neoad ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
TPS10128 Background: Adjuvant endocrine therapy (AET) is a crucial component of treatment used to prevent recurrence and reduce mortality for women with hormone receptor positive breast cancer. Poor adherence to AET is a signific ...
Full textCite